NKX3.1 versus cyclin D1 expression in prostatic adenocarcinoma: a comparative study
Conclusion
NKX3.1 antibody can be used for early detection of the PAC and treatment must be focused more on NKX3.1 than cyclin D1 inhibitors.
Source: Egyptian Journal of Pathology - Category: Pathology Tags: Original Articles Source Type: research
More News: Adenocarcinoma | Benign Prostatic Hyperplasia | Cancer | Cancer & Oncology | Egypt Health | Genetics | Pathology | Study